Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study

Kendler, David L.; Macarios, David; Lillestol, Michael; Moffett, Alfred H.; Satram‐Hoang, Sacha; Huang, Joice; Kaur, Primal; Tang, En-Tzu; Wagman, Rachel B.; Horne, Rob

doi:10.1097/gme.0b013e31828f5e5d

Cited by 34 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Injectable preparations including teriparatide, denosumab, and zoledronic acid had significantly higher compliance rates compared with oral preparations such as strontium ranelate, raloxifene, and bisphosphonates ( P < .0001). These findings are consistent with previous studies and reinforce the common perception that injectable drugs can overcome some of the barriers of oral therapy, such as cumbersome administration instructions and gastrointestinal side effects and improve treatment adherence . Compliance with teriparatide was 85.5%, whereas compliance to denosumab and zoledronic acid was 100%.…”

Section: Discussionsupporting

confidence: 90%

“…A few studies have shown that patients receiving osteoporosis treatment prefer therapeutic regimens with longer periods between doses . In this study, most patients preferred annual treatment, and only a few chose twice‐yearly treatment.…”

Section: Discussionmentioning

confidence: 86%

“…A few studies have shown that patients receiving osteoporosis treatment prefer therapeutic regimens with longer periods between doses. 13,26,30,31 In this study, most patients preferred annual treatment, and only a few chose twice-yearly treatment. In Israel, zoledronic acid (Aclasta) became available in 2008, whereas denosumab (Prolia), a relatively new drug, was launched in 2012.…”

Section: Discussionmentioning

confidence: 91%

“…These findings are consistent with previous studies and reinforce the common perception that injectable drugs can overcome some of the barriers of oral therapy, such as cumbersome administration instructions and gastrointestinal side effects and improve treatment adherence. 19,20,26,27 Compliance with teriparatide was 85.5%, whereas compliance to denosumab and zoledronic acid was 100%. Teriparatide is given daily to patients with very high fracture risk or to those in whom bisphosphonate therapy has failed.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

Eliasaf

Amitai

Edry

et al. 2016

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Osteoporosis treatments reduce the risk of fractures by 30%-50%, but adherence after 1 year is only about 50%. Drug holiday, a period with no active treatment, is part of routine management. The objective of this study was to determine compliance and persistence with osteoporosis therapy among postmenopausal women and to assess attitudes regarding treatment resumption among patients on drug holiday. This was a prospective observational study of patients followed at a dedicated metabolic bone clinic September 2013-February 2014. Compliance was assessed by medication possession ratio (MPR; number of doses dispensed relative to the number prescribed). Persistence was defined as continuation of treatment without a >30-day gap in prescription refills. Of 150 patients (70.1 ± 8.1 years), 57% were prescribed a medication: 64% oral, mostly bisphosphonates. MPR ≥ 80% was found in 80% and <50% in 12%; it was 100% for zoledronic acid and denosumab and 97%, 85%, 83%, and 70% for raloxifene, teriparatide, oral bisphosphonates, and strontium ranelate, respectively. Of 39 patients prescribed oral bisphosphonates, 77% persisted with treatment, and 89% took them as directed. Of 64 patients on a drug holiday, 59% expressed confidence in their physician's future treatment choice, whereas 19% expressed concerns about resuming treatment. Compliance among patients attending a dedicated bone clinic was higher than that reported in the literature. High persistence and compliance may be specific to patients followed in this type of setting. This study provides new information about attitudes of patients on a drug holiday. Most were not concerned about resuming treatment and did not have a preferred medication.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

Eliasaf

Amitai

Edry

et al. 2016

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Medication adherence has been shown to be better with denosumab than with bisphosphonates. A study by Kendler et al (27) reported greater treatment satisfaction when patients transitioned to denosumab as compared to switching to a monthly oral bisphosphonate. Another study by Palacios et al (28) showed that participants preferred denosumab to alendronate while on treatment and had more positive perceptions of it, which were also associated with better adherence.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review

Chandran¹,

Venkatachalam²

2019

smedj

View full text Add to dashboard Cite

RESULTS Nine studies were eligible for inclusion. They were further categorised into six cohort groups. All studies had denosumab with oral bisphosphonates as the active comparator. Four out of six cohort studies showed significant improvements in bone strength (p < 0.001) at the distal radius, tibia, total hip, femoral neck, lumbar spine and trochanter at 12 months for patients on denosumab compared to the bisphosphonate group. Serum C-telopeptide of cross-linked collagen, a bone turnover marker, was consistently lower in the denosumab group in all studies. There were no significant differences in hypocalcaemia, atypical fractures, fragility fractures, osteonecrosis of the jaw, all infections (including fever or influenza-like symptoms), gastrointestinal side effects or dermatological conditions in all studies, except for one that did not document side effects. CONCLUSION Denosumab can be used both as a first-line agent and an alternative to bisphosphonate in the treatment of postmenopausal osteoporosis. There is currently insufficient data to show that denosumab is not inferior to bisphosphonates in fracture prevention.

show abstract

Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers

Nogués

Carbonell

Canals

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Osteoporosis is a systemic skeletal disease characterized by low bone mass and microstructural deterioration of bone tissues, resulting in bone fragility and increased fracture risk. It is the most common bone‐related disease in the population. However, the proportion of patients who start treatment but discontinue it during the first year is very high (around 50%). Endeavors are made to promote patient participation in treatment by implementing patient decision aids (PDA), whose function is to help the patient make disease‐related decisions. We aim to summarize the characteristics of the currently available PDA for osteoporosis, as well as deciding factors. Methods Comprehensive review of the literature. Results Currently, eleven PDAs can be found for osteoporosis. These PDA have different characteristics or options such as information about treatments tailored to patient needs, graphic information of the results (to facilitate understanding), personal histories (learning), tests to check the knowledge acquired, provision of evidence, clinical practice guidelines or a final summary to share with their doctor. Only five of these PDAs can be considered complete since they provide relevant disease information and therapeutic options to the patient, promote patient's reflection and foment patient‐physician discussion. Conclusions This study provides an update on the current state of decision making on osteoporosis and available PDA, which can help engage the patient through shared decision‐making by considering, among other things, patient preferences. Physicians should consider PDA, as it may promote adherence and effectiveness of treatment.

show abstract

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study

Abstract: Participants preferred denosumab to alendronate while on treatment and had more positive perceptions of denosumab than alendronate. These perceptions were associated with better adherence.

Cited by 34 publications

References 30 publications

Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review

Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers

Contact Info

Product

Resources

About